Michael Becker to Middle Aged
This is a "connection" page, showing publications Michael Becker has written about Middle Aged.
Connection Strength
0.652
-
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
Score: 0.037
-
Myocardial deformation by strain echocardiography identifies patients with acute coronary syndrome and non-diagnostic ECG presenting in a chest pain unit: a prospective study of diagnostic accuracy. Clin Res Cardiol. 2016 Mar; 105(3):248-56.
Score: 0.034
-
An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
Score: 0.033
-
Detection of coronary artery disease in postmenopausal women: the significance of integrated stress imaging tests in a 4-year prognostic study. Clin Res Cardiol. 2015 Mar; 104(3):258-71.
Score: 0.032
-
The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leuk Res. 2013 Sep; 37(9):1052-6.
Score: 0.029
-
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
Score: 0.029
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
Score: 0.028
-
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
Score: 0.026
-
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011; 14(1):10-5.
Score: 0.024
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
Score: 0.023
-
Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009 May; 36(5):1041-8.
Score: 0.022
-
Survival and quality of life in patients with cardiac resynchronization therapy for severe heart failure and in heart transplant recipients within a contemporary heart failure management program. J Heart Lung Transplant. 2008 Jul; 27(7):746-52.
Score: 0.020
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
Score: 0.017
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
Score: 0.016
-
Sex on the internet: furthering our understanding of men with online sexual problems. Psychol Addict Behav. 2004 Sep; 18(3):223-30.
Score: 0.016
-
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug; 31(8):1575-81.
Score: 0.016
-
Rheumatoid hyperviscosity syndrome: reversibility of microvascular abnormalities after treatment. Am J Ophthalmol. 2002 Jul; 134(1):130-2.
Score: 0.013
-
Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. Kidney Blood Press Res. 2019; 44(4):690-703.
Score: 0.011
-
Electronic Health Record Mortality Prediction Model for Targeted Palliative Care Among Hospitalized Medical Patients: a Pilot Quasi-experimental Study. J Gen Intern Med. 2019 09; 34(9):1841-1847.
Score: 0.011
-
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
Score: 0.011
-
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
Score: 0.010
-
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29; 378(13):1200-1210.
Score: 0.010
-
Use of two-dimensional speckle tracking echocardiography to predict cardiac events: Comparison of patients with acute myocardial infarction and chronic coronary artery disease. Clin Cardiol. 2018 Jan; 41(1):111-118.
Score: 0.010
-
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul; 76(7):1207-1218.
Score: 0.009
-
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 08; 68(8):2035-43.
Score: 0.009
-
Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):372-378.
Score: 0.009
-
Current Orthopaedic Surgeon Practices for Nonarthroplasty Treatment of Osteoarthritis of Adult Hip and Knee. J Surg Orthop Adv. 2015; 24(4):213-20.
Score: 0.008
-
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
Score: 0.008
-
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
Score: 0.008
-
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1745-52.
Score: 0.007
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
Score: 0.007
-
A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec; 37(12):1622-7.
Score: 0.007
-
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol. 2012 May; 71(5):614-23.
Score: 0.007
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
Score: 0.007
-
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
Score: 0.006
-
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.
Score: 0.006
-
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
Score: 0.006
-
Registration of coronary venous anatomy to the site of the latest mechanical contraction. Acta Cardiol. 2010 Apr; 65(2):161-70.
Score: 0.006
-
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
Score: 0.005
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
Score: 0.005
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
Score: 0.005
-
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
Score: 0.005
-
The SPINK1 N34S variant is associated with acute pancreatitis. Eur J Gastroenterol Hepatol. 2008 Aug; 20(8):726-31.
Score: 0.005
-
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
Score: 0.005
-
Phosphoribosylpyrophosphate synthetase superactivity. A study of five patients with catalytic defects in the enzyme. Arthritis Rheum. 1986 Jul; 29(7):880-8.
Score: 0.004
-
Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract. 2006 Apr; 60(4):408-14.
Score: 0.004
-
Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol. 2005 Dec; 32(12):2368-72.
Score: 0.004
-
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
Score: 0.004
-
Phosphoribosylpyrophosphate synthetase superactivity: detection, characterization of underlying defects, and treatment. Adv Exp Med Biol. 1984; 165 Pt A:91-96.
Score: 0.004
-
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
Score: 0.004
-
A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8.
Score: 0.004
-
Hip involvement in ankylosing spondylitis. Arthritis Rheum. 1976 Jul-Aug; 19(4):683-92.
Score: 0.002
-
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb; 57(2):308-18.
Score: 0.002
-
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug; 55(2):232-42.
Score: 0.002